Pan-cancer biomarkers of immune therapy resistance: mechanisms and clinical translation.
- 1Department of Gastric Surgery, Liaoning Cancer Hospital & Institute, Shenyang, China.
Abstract
Immune checkpoint blockade targeting PD-1/PD-L1 has reshaped cancer therapy across multiple tumor types. However, primary and acquired resistance remain major barriers to durable clinical benefit. Increasing evidence indicates that immunotherapy resistance is not driven by isolated molecular alterations, but by coordinated changes involving tumor-intrinsic immune escape, immunosuppressive tumor microenvironments, systemic inflammatory remodeling, and adaptive biomarker evolution under therapeutic pressure. This review focuses on pan-cancer biomarkers of immune therapy resistance from the perspective of mechanisms and clinical translation. First, we summarize targetable biomarker classes that link resistance biology to therapeutic sensitization across cancers, including transcription factors, genomic alterations, immune checkpoint proteins and metabolic regulators. For each class, we highlight representative cancer types in which experimental or clinical evidence supports their role in immunotherapy resistance. Second, we discuss the mechanistic basis of resistance-associated biomarkers, emphasizing antigen presentation defects, impaired interferon signaling, oncogenic pathway activation, T-cell exhaustion, myeloid and stromal immunosuppression, metabolic reprogramming, and dynamic systemic immune remodeling. These mechanisms provide a biological perspective for interpreting biomarkers not only as predictors of treatment response, but also as functional indicators of resistance evolution. By integrating biomarker classification, resistance mechanisms, and therapeutic sensitization strategies, this review aims to provide a new perspective for using pan-cancer resistance biomarkers to guide rational combination immunotherapy and improve precision cancer treatment.
Related
- Targeting the Tumor Microenvironment Network to Overcome Immunotherapy Resistance in Non‐Small Cell Lung Cancer: Mechanisms to Clinical Translation
- [Mechanisms and Clinical Translation Advances of Physical Targeted Therapy for Malignant Pleural Effusion].
- Ferroptosis in cancer: molecular mechanisms, tumour microenvironment, therapeutic resistance, and clinical translation.
- AI-driven multi-omics biomarkers in precision breast cancer therapeutics: from discovery to clinical translation
- Circulating Biomarkers with Artificial Intelligence for Clinical Risk Assessment and Therapeutic Monitoring: Evidence, Limitations, and Translation
BibTeX
@article{wang2026pancancer,
title = {{Pan-cancer biomarkers of immune therapy resistance: mechanisms and clinical translation.}},
author = {Chao Wang and Dong Yang},
journal = {Frontiers in cell and developmental biology},
year = {2026},
month = oct,
doi = {10.3389/fcell.2026.1895670},
url = {https://europepmc.org/article/MED/42909279},
note = {CC BY},
}
RIS
TY - JOUR
TI - Pan-cancer biomarkers of immune therapy resistance: mechanisms and clinical translation.
AU - Chao Wang
AU - Dong Yang
PY - 2026
DA - 2026/10/07
JO - Frontiers in cell and developmental biology
DO - 10.3389/fcell.2026.1895670
UR - https://europepmc.org/article/MED/42909279
AB - Immune checkpoint blockade targeting PD-1/PD-L1 has reshaped cancer therapy across multiple tumor types. However, primary and acquired resistance remain major barriers to durable clinical benefit. Increasing evidence indicates that immunotherapy resistance is not driven by isolated molecular alterations, but by coordinated changes involving tumor-intrinsic immune escape, immunosuppressive tumor microenvironments, systemic inflammatory remodeling, and adaptive biomarker evolution under therapeutic pressure. This review focuses on pan-cancer biomarkers of immune therapy resistance from the perspective of mechanisms and clinical translation. First, we summarize targetable biomarker classes that link resistance biology to therapeutic sensitization across cancers, including transcription factors, genomic alterations, immune checkpoint proteins and metabolic regulators. For each class, we highlight representative cancer types in which experimental or clinical evidence supports their role in immunotherapy resistance. Second, we discuss the mechanistic basis of resistance-associated biomarkers, emphasizing antigen presentation defects, impaired interferon signaling, oncogenic pathway activation, T-cell exhaustion, myeloid and stromal immunosuppression, metabolic reprogramming, and dynamic systemic immune remodeling. These mechanisms provide a biological perspective for interpreting biomarkers not only as predictors of treatment response, but also as functional indicators of resistance evolution. By integrating biomarker classification, resistance mechanisms, and therapeutic sensitization strategies, this review aims to provide a new perspective for using pan-cancer resistance biomarkers to guide rational combination immunotherapy and improve precision cancer treatment.
SN - 2296-634X
ER -